|
Market Closed -
Toronto S.E.
21:57:56 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.1200 CAD | -.--% |
|
-7.69% | -29.41% |
| 10-31 | Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2026 | CI |
| 10-02 | Voyageur Pharmaceuticals Settles CA$192,300 Debt by Issuing Shares | MT |
Company Valuation: Voyageur Pharmaceuticals Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: November | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 2.855 | 9.164 | 8.025 | 5.308 | 9.066 | 28.55 |
| Change | - | 221.01% | -12.43% | -33.85% | 70.79% | 214.92% |
| Enterprise Value (EV) 1 | 3.197 | 8.387 | 8.013 | 5.343 | 8.953 | 28.32 |
| Change | - | 162.35% | -4.46% | -33.32% | 67.58% | 216.31% |
| P/E | -2.48x | -4.15x | -4.3x | -3.73x | -5.24x | -7.5x |
| PBR | 9.32x | 4.81x | 5.52x | 3.7x | 20.1x | 22.8x |
| PEG | - | -0.1x | 0.2x | 0.1x | -0.3x | -0.1x |
| Capitalization / Revenue | - | - | - | - | - | 2,443,311,938x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -3.25x | -4.25x | -5.02x | -4.38x | -5.92x | -9.79x |
| EV / EBIT | -2.81x | -4.25x | -4.99x | -4.37x | -5.91x | -9.79x |
| EV / FCF | -58.1x | -7.96x | -6.73x | -9.15x | 14.8x | -17x |
| FCF Yield | -1.72% | -12.6% | -14.8% | -10.9% | 6.74% | -5.89% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0162 | -0.0217 | -0.0163 | -0.0107 | -0.0124 | -0.0213 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | 0.0117 |
| EBITDA 1 | -0.9846 | -1.972 | -1.596 | -1.221 | -1.513 | -2.892 |
| EBIT 1 | -1.138 | -1.974 | -1.605 | -1.223 | -1.515 | -2.893 |
| Net income 1 | -1.139 | -2.051 | -1.754 | -1.399 | -1.707 | -3.533 |
| Net Debt 1 | 0.3422 | -0.7768 | -0.012 | 0.0344 | -0.1126 | -0.2306 |
| Reference price 2 | 0.0400 | 0.0900 | 0.0700 | 0.0400 | 0.0650 | 0.1600 |
| Nbr of stocks (in thousands) | 71,366 | 101,820 | 114,638 | 132,702 | 139,473 | 178,438 |
| Announcement Date | 3/30/21 A | 3/17/22 A | 3/30/23 A | 3/26/24 A | 3/31/25 A | 3/27/26 A |
1CAD in Million2CAD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 19.47M | |
| 41.42x | 14.04x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 36.71x | 8.6x | 17.71x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 106.24x | 6.06x | 25.8x | 2.28% | 369B | |
| 23.19x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.47x | 4.89x | 13.59x | 1.77% | 290B | |
| 29.55x | 7.53x | 13.48x | 2.16% | 252B | |
| -41.18x | 7.46x | 46.76x | 1.93% | 212B | |
| Average | 31.35x | 7.39x | 21.65x | 2.01% | 426.19B | |
| Weighted average by Cap. | 37.16x | 8.83x | 22.81x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VM Stock
- Valuation Voyageur Pharmaceuticals Ltd.
Select your edition
All financial news and data tailored to specific country editions
